ADM Tronics Unlimited, Inc. (OTCQB: ADMT) has announced its financial results for the fiscal year that concluded on March 31, 2026. The company reported a revenue increase of approximately 5% compared to the previous fiscal year, bringing total revenues to $3,347,082, up from $3,197,110 in 2025.
The revenue growth for FY 2026 was primarily attributed to an increase in the electronic medical device segment, which generated an additional $311,916, and a rise in chemical segment revenues by $72,876. However, this was partially countered by a decrease in engineering services revenue, which fell by $234,820.
Despite the revenue increase, ADM Tronics reported a net loss of $100,374, an improvement from a net loss of $123,056 in the previous fiscal year, indicating ongoing challenges in achieving profitability. The company’s gross profit decreased to approximately 41% of revenues, compared to 43% in the previous year.
During the fiscal year, ADM Tronics made significant strides in regulatory compliance. The company successfully achieved ISO 13485 recertification on April 6, 2026, in anticipation of new regulations implemented by the U.S. Food and Drug Administration (FDA). This recertification demonstrates ADM Tronics’ commitment to maintaining high-quality standards in medical device development.
Additionally, the company is preparing to seek FDA 510(k) clearance for the commercialization of its proprietary Sonotron® technology, a system aimed at addressing non-invasive pain management, one of healthcare’s substantial unmet needs.
Another highlight from the fiscal year includes the commercial launch of the Vet-Sonotron®, a veterinary adaptation of the Sonotron technology designed to offer non-invasive pain management solutions for animal healthcare. The company is actively pursuing distribution partnerships to facilitate market introduction.
ADM Tronics continued investing in innovation, with research and development expenses increasing to $544,971 from $517,275 in the prior year. The company maintained a focus on enhancing its product lineup while slightly reducing selling, general, and administrative expenses.
During fiscal year 2026, ADM Tronics Unlimited, Inc. (OTCQB: ADMT) advanced the development of its proprietary Sonotron® technology for human medicine, aimed at addressing non-invasive pain management needs. The Company achieved ISO 13485 recertification, indicating regulatory readiness. Additionally, the Vet-Sonotron®, a veterinary version of the technology, was commercially launched and distribution partnerships are being pursued.
For the fiscal year ended March 31, 2026, ADM Tronics reported revenues of $3,347,082, an increase of approximately 5% from $3,197,110 in the previous fiscal year. However, gross profit decreased to $1,355,424 (41%) from $1,395,660 (43%). The net loss reduced to $100,374 from $123,056 year-over-year.
ADM Tronics achieved significant regulatory milestones during fiscal year 2026, including alignment with the new Quality Management System Regulation (QMSR) initiated by the FDA and successfully obtaining ISO 13485 recertification on April 6, 2026. These steps reflect the Company’s commitment to maintaining high standards in medical device quality management.
ADM Tronics faces various risks including regulatory challenges related to FDA clearances, market competition, and the successful commercialization of its proprietary technologies. The Company has acknowledged that forward-looking statements may involve uncertainties that could cause actual results to differ from expectations.
ADM Tronics is focusing on the continued advancement of its Sonotron® technology, particularly its application in human healthcare for non-invasive pain management. Additionally, the Company aims to pursue FDA 510(k) clearance for its medical devices and expand its distribution partnerships for the Vet-Sonotron® in the veterinary market.
ADM Tronics generates revenue from three main areas: proprietary medical devices, medical device engineering services, and chemical segment sales. In fiscal year 2026, the electronic medical device segment saw a revenue increase of $311,916, while the engineering services segment experienced a decrease of $234,820.
ADM Tronics describes its core competencies as the ability to conceptualise new technologies, develop them in-house, and transition them into manufacturing and commercialization. The Company operates across multiple sectors, including proprietary medical devices and eco-friendly formulations.
Investors can access complete financial results for ADM Tronics in the Company's Annual Report on Form 10K available at www.sec.gov.